Comparison of Liquid Chromatography-Tandem Mass Spectrometry, RIA, and ELISA Methods for Measurement of Urinary Estrogens
- 1 January 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (1), 292-300
- https://doi.org/10.1158/1055-9965.epi-09-0643
Abstract
Absolute and relative concentrations of estrogens and estrogen metabolites are important for clinical decisions as well as for epidemiologic, experimental, and clinical research on hormonal carcinogenesis. RIA and ELISA are routinely used for measuring estrogen metabolites in blood and urine due to efficiency and low cost. Here, we compare absolute and ranked concentrations of estrone, estradiol, and estriol measured by indirect RIA and of 2-hydroxyestrone and 16α-hydroxyestrone measured by ELISA to the concentrations obtained using a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, which measures 15 estrogen metabolites concurrently. We used overnight urine samples collected from control women (362 premenopausal and 168 postmenopausal) participating in a population-based case-control study of breast cancer among Asian American women ages 20 to 55 years. When comparing RIA or ELISA levels to LC-MS/MS, absolute concentrations for the five estrogen metabolites ranged from 1.6 to 2.9 and 1.4 to 11.8 times higher in premenopausal and postmenopausal women, respectively (all P < 0.0001). However, LC-MS/MS measurements were highly correlated [Spearman r (rs) = 0.8-0.9] with RIA and ELISA measurements in premenopausal women and moderately correlated (rs = 0.4-0.8) in postmenopausal women. Measurements of the 2-hydroxyestrone:16α-hydroxyestrone ratio, a putative biomarker of breast cancer risk, were moderately correlated in premenopausal women (rs = 0.6-0.7) but only weakly correlated in postmenopausal women (rs = 0.2). LC-MS/MS had higher intraclass correlation coefficients (≥99.6%) and lower coefficients of variation (≤9.4%) than ELISA (≥97.2% and ≤14.2%) and RIA (≥95.2% and ≤17.8%). Comparison with the LC-MS/MS method suggests that the widely used RIA and ELISA estrogen metabolite measures may be problematic, especially at low estrogen metabolite levels characteristic of postmenopausal women. Cancer Epidemiol Biomarkers Prev; 19(1); 292–300Keywords
This publication has 34 references indexed in Scilit:
- Estrogen Hydroxylation—The Good and the BadAnnals of the New York Academy of Sciences, 2009
- Circulating 2-Hydroxy- and 16α-Hydroxy Estrone Levels and Risk of Breast Cancer among Postmenopausal WomenCancer Epidemiology, Biomarkers & Prevention, 2008
- Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapySteroids, 2007
- Estrogen Carcinogenesis in Breast CancerNew England Journal of Medicine, 2006
- Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutritionEndocrine-Related Cancer, 2005
- Measuring Fifteen Endogenous Estrogens Simultaneously in Human Urine by High-Performance Liquid Chromatography-Mass SpectrometryAnalytical Chemistry, 2005
- Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective StudiesJNCI Journal of the National Cancer Institute, 2002
- A Pilot Study of Urinary Estrogen Metabolites (16α-OHE 1 and 2-OHE 1 ) in Postmenopausal Women with and without Breast CancerEnvironmental Health Perspectives, 1997
- Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breast cancer risk.Environmental Health Perspectives, 1995
- Migration Patterns and Breast Cancer Risk in Asian-American WomenJNCI Journal of the National Cancer Institute, 1993